Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Abiraterone Acetate Tablets (I) vs ZYTIGA in mCRPC
NCT04862091Phase 2Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Hengrui. Primary endpoint: Serum testosterone concentration at Day 10. Started Apr 2021; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04862091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04862091.